TransEnterix

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

TransEnterix (TRXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

TransEnterix (TRXC) Looks Good: Stock Adds 7.9% in Session

Investors are probably going to do a double-take when they look at the five-year price chart for TransEnterix Inc. (TRXC). The North Carolina-based medical device company traded as high as $90 just more than two years ago.

TransEnterix and Butterfly Among Medtech M&A Opportunities

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are pleased to support Southern Surgical Hospital in advancing care with the addition of the Senhance Surgical System,” said Anthony Fernando, Pre

TransEnterix Announces Southern Surgical Hospital to Initiate a Senhance® Digital Laparoscopic Program

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Senhance® Surgical System has received its registration certificate by Roszdravnadzor, the Russian medical device regulatory agency allowing for its sale and utilization throughout the Russian Federation. “Russian regulatory approval is an important mil

TransEnterix Announces Approval of Senhance® Surgical System in Russian Federation

TransEnterix (TRXC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes TransEnterix (TRXC) a New Buy Stock

Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.

Do Options Traders Know Something About TransEnterix (TRXC) Stock We Don't?

Transenterix, Inc.'s (TRXC) CEO Anthony Fernando on Q3 2020 Results - Earnings Call Transcript

TransEnterix (TRXC) delivered earnings and revenue surprises of 47.83% and 11.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

TransEnterix (TRXC) Reports Q3 Loss, Tops Revenue Estimates

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the third quarter of 2020. Recent Highlights Year-to-date, eight clinical programs initiated with one additional system pending installation and over 1,200 procedures performed globally First procedures performed in the U

TransEnterix, Inc. Reports Operating and Financial Results for the Third Quarter 2020

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at the Stifel 2020 Virtual Healthcare Conference. The virtual presentation is scheduled to take place at 4:00 pm Eastern Time, Tuesday, November 17, 2020. A live audio webcast of the conference presentation will be available online at the inves

TransEnterix to Present at the Stifel 2020 Virtual Healthcare Conference

TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TransEnterix (TRXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC) announced today that it plans to release third quarter financial and operating results after the market closes on Thursday, November 5, 2020. The Company will host a conference call to discuss these results starting at 4:30 p.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-931-4071 for domestic callers and 1-303-223-01

TransEnterix Schedules Third Quarter Financial and Operating Results Conference Call for November 5, 2020

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that surgeons at Maastricht University Medical Center+ (MUMC+) in the Netherlands, have successfully operated on multiple pediatric patients, becoming the first pediatric surgical program in the world to utilize the Senhance® Surgical System and integrate digita

TransEnterix Announces First Pediatric Surgical Cases with Senhance® Surgical System

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are excited to partner with Toshima Hospital to build its Senhance Digital Laparoscopy Progra

TransEnterix Announces Toshima Hospital in Japan to Initiate a Senhance® Digital Laparoscopy Program

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Hackensack Meridian Health Pascack Valley Medical Center, a hospital in New Jersey, successfully completed its first surgical procedures using the Intelligent Surgical UnitTM (ISU™). The technology previously received FDA clearance, and currently enables ma

TransEnterix Ushers in New Era of Robotic Surgery with First Usage of Machine Vision Capabilities

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc.

TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System

TransEnterix to Present at the H. C. Wainwright 22nd Annual Global Investment Conference

TransEnterix Announces New Employment Inducement Grant

TransEnterix Announces Appointment of Shameze Rampertab as Chief Financial Officer

Transenterix, Inc. (TRXC) CEO Anthony Fernando on Q2 2020 Results - Earnings Call Transcript

TransEnterix (TRXC) delivered earnings and revenue surprises of 44.74% and 127.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates

RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2020.

News for TransEnterix Stock (TRXC)